This is a market research study being conducted by CRC Research, a Canadian market research company, to
gather findings and insights to aid in better understanding the patient experience and improve the outcomes of
those with Parkinson disease who use subcutaneous foscarbidopa-foslevodopa infusion (VYALEV®).
Understanding the Patient Experience for those with Parkinson disease who use SubcutaneousFoscarbidopa-Foslevodopa Infusion (VYALEV®)
- Run Dates:
- Ongoing
Who is eligible to participate in the study?
- People with Parkinson disease and/or the Care Partners
- At least 45 years of age
- Who have or has a loved one who has current and/or previous experience with the treatment Vyalev
- Have access to a telephone, computer, or tablet
What is required of the participants?
Participants will be required to complete online screening questions to verify their eligibility (26 questions/ approx. 15 minutes). Once verification is complete participants will then take part in a 60-minute in-depth interview about their experience with Vyalev®
An honorarium of $137.50/person with Parkinson’s and/or $110/care partner will be paid to anyone who qualifies and completes the interview in full.
To begin the participation process, click the link below: Link: https://crcconsumerresearch.ca/index.php?r=survey/index&sid=734616&lang=en
- University:
- None
- Contact:
- Eva Woo
- eva@crcresearch.com
- 7783288875
- Ethics ID:
- CRIC Study Verification Code: 20241209-CR109
